Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (128)	3/11/2000 3:46:00 PM
From: tuck	Respond to of 1833

Richard, I've had a couple of good times on tall ships, and I hope you and your son enjoyed yourselves, too. Now back to work! ;~} Seriously, whenever; you've got a life outside of cyberspace. Thanks in Advance for your Assistance. Cheers, Tuck

To: scaram(o)uche who wrote (128)	3/14/2000 12:27:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

Tuesday March 14, 12:00 pm Eastern Time Company Press Release SOURCE: CV Therapeutics, Inc. Phase I Results of CV Therapeutics' CVT-510 Presented at the American College Of Cardiology 49th Annual Scientific Session ANAHEIM, Calif., March 14 /PRNewswire/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - news) today announced the presentation of results from the Phase I trial of CVT-510 at the American College of Cardiology 49th Annual Scientific Session. CVT-510, a selective adenosine A1 receptor agonist, is being developed for the potential treatment of atrial arrhythmias. The objective of this initial trial was to evaluate tolerable doses and to assess the potential effect on heart rate in human volunteers. The trial data indicated that CVT-510 may be a potential therapeutic option for immediate and sustained control of rapid heart rate with minimal effects on blood pressure or normal heart rates. ``The results of the first human trial are encouraging,' said Luiz Belardinelli, M.D., Executive Director, Pharmacological Sciences, CV Therapeutics, Palo Alto, CA. ``These data demonstrate that CVT-510 may slow the heart rate by selectively targeting the adenosine A1 receptor, which is responsible for regulating AV nodal conduction, without affecting the adenosine A2 receptor, which can lower blood pressure. We hope to further confirm these findings as we evaluate CVT-510 in our ongoing Phase II clinical trial in patients with atrial arrhythmias.' Accelerated transmission of electrical impulses through the atrioventricular (AV) node, a critical regulator of heart rate, is largely responsible for the rapid heart rate during many atrial arrhythmias, such as atrial fibrillation, atrial flutter and paroxysmal atrial tachycardias. Prompt slowing of AV nodal conduction is often the immediate goal of treatment to slow the abnormally rapid heart rate. Atrial arrhythmias are responsible for nearly 2.6 million hospitalizations annually in the U.S., and are potentially life threatening situations with such consequences as stroke, heart attack and low blood pressure and require immediate treatment. Caffeine, tobacco and stress may trigger an increase in the speed of conduction through the AV node resulting in atrial arrhythmias. Different from traditional adenosine medications that target all the adenosine receptors, CVT-510 has been designed to selectively target the adenosine A1 receptor without significantly stimulating the adenosine A2 receptor, which can control blood pressure levels. Thus, CVT-510 may slow irregular heart rates without significantly affecting blood pressure rates. Statements in this press release concerning the potential of CVT-510 are forward-looking statements that involve risks and uncertainties, including, but not limited to, uncertainties related to CVT's early stage of development and clinical trials. Actual results could differ materially. Factors that could cause or contribute to such differences are more fully discussed in CVT's Prospectus dated October 6, 1999. CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CVT is currently conducting clinical trials for two of its products. Ranolazine, the first in a new class of compounds known as partial fatty acid oxidation (pFOX) inhibitors for the potential treatment of angina, is in Phase III clinical trials. CVT-510, for the potential treatment of atrial arrhythmias, is in Phase II clinical trials. For more information, please visit CV Therapeutics' web site at www.cvt.com. SOURCE: CV Therapeutics, Inc.